Selecta Biosciences, Inc.

As of May 4, 2023, Selecta Biosciences, Inc. is considered overvalued with negative valuation ratios and a year-to-date stock return of -42.43%, significantly underperforming compared to the S&P 500's 12.22% gain.

As of May 4, 2023, Selecta Biosciences, Inc. is considered overvalued and risky due to negative financial metrics, including a price-to-book value of -13.03 and an EV to EBITDA of -2.85, alongside a year-to-date stock performance decline of 45.11%.

As of June 6, 2025, the trend is mildly bearish due to daily moving averages indicating a bearish trend, while weekly indicators like the MACD show mild bullishness, resulting in a mixed outlook overall.

As of March 2022, the management team of Selecta Biosciences, Inc. includes Ms. Carrie Cox as Independent Chairman and Dr. Carsten Brunn as President and CEO, along with several Independent Directors on the Board.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immune-modulating therapies for rare diseases. As of March 2025, it reported net sales of $1 million and a net loss of $18 million, with a market cap of $251.85 million.

As of Jun 18, Selecta Biosciences, Inc. has a market capitalization of 251.85 million, with net sales of 40.78 million and a net profit of -89.08 million over the last four quarters. The company reported shareholder's funds of -6.80 million and total assets of 435.02 million as of Dec 24.